Report Sections

See All Reports

  • HP:0100754: Mania
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0100754: Mania

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (5)


    Name (Synonyms) Correlation
    drug376 BIO101 Wiki 0.71
    drug697 Cannabis, Medical Wiki 0.71
    drug1945 MagPro X100 Stimulator, B70 Fluid-Cooled Coil Wiki 0.50
    Name (Synonyms) Correlation
    drug589 COVID Convalescent Plasma Wiki 0.50
    drug2490 Placebo Wiki 0.03

    Correlated MeSH Terms (29)


    Name (Synonyms) Correlation
    D001714 Bipolar Disorder NIH 0.82
    D000070627 Chronic Traumatic Encephalopathy NIH 0.71
    D005879 Tourette Syndrome NIH 0.71
    Name (Synonyms) Correlation
    D003424 Crohn Disease NIH 0.71
    D000070642 Brain Injuries, Traumatic NIH 0.50
    D000690 Amyotrophic Lateral Sclerosis NIH 0.50
    D012640 Seizures NIH 0.50
    D016472 Motor Neuron Disease NIH 0.50
    D006526 Hepatitis C NIH 0.50
    D005356 Fibromyalgia NIH 0.35
    D000755 Anemia, Sickle Cell NIH 0.35
    D001930 Brain Injuries, NIH 0.32
    D001927 Brain Diseases NIH 0.32
    D010300 Parkinsonian NIH 0.29
    D015212 Inflammatory Bowel Diseases NIH 0.27
    D012598 Scoliosi NIH 0.25
    D009103 Multiple Sclerosis NIH 0.25
    D059350 Chronic Pain NIH 0.24
    D003866 Depressive Disorder NIH 0.14
    D040921 Stress Disorders, Traumatic NIH 0.14
    D004194 Disease NIH 0.14
    D013313 Stress Disorders, Post-Traumatic NIH 0.13
    D014947 Wounds and Injuries NIH 0.13
    D003863 Depression, NIH 0.09
    D013577 Syndrome NIH 0.07
    D003141 Communicable Diseases NIH 0.05
    D007239 Infection NIH 0.03
    D045169 Severe Acute Respiratory Syndrome NIH 0.03
    D018352 Coronavirus Infections NIH 0.02

    Correlated HPO Terms (8)


    Name (Synonyms) Correlation
    HP:0100280 Crohn's disease HPO 0.71
    HP:0006802 Abnormal anterior horn cell morphology HPO 0.50
    HP:0007354 Amyotrophic lateral sclerosis HPO 0.50
    Name (Synonyms) Correlation
    HP:0001250 Seizure HPO 0.41
    HP:0001298 Encephalopathy HPO 0.32
    HP:0002037 Inflammation of the large intestine HPO 0.27
    HP:0012532 Chronic pain HPO 0.24
    HP:0000716 Depressivity HPO 0.14

    Clinical Trials

    Navigate: Correlations   HPO

    There are 2 clinical trials


    1 Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19

    This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

    NCT03944447
    Conditions
    1. Chronic Pain
    2. Chronic Pain Syndrome
    3. Chronic Pain Due to Injury
    4. Chronic Pain Due to Trauma
    5. Fibromyalgia
    6. Seizures
    7. Hepatitis C
    8. Cancer
    9. Crohn Disease
    10. HIV/AIDS
    11. Multiple Sclerosis
    12. Traumatic Brain Injury
    13. Sickle Cell Disease
    14. Post Traumatic Stress Disorder
    15. Tourette Syndrome
    16. Ulcerative Colitis
    17. Glaucoma
    18. Epilepsy
    19. Inflammatory Bowel Diseases
    20. Parkinson Disease
    21. Amyotrophic Lateral Sclerosis
    22. Chronic Traumatic Encephalopathy
    23. Anxiety
    24. Depression
    25. Insomnia
    26. Autism
    27. Opioid-use Disorder
    28. Bipolar Disorder
    29. Covid19
    30. SARS-CoV Infection
    31. COVID-19
    32. Corona Virus Infection
    33. Coronavirus
    Interventions
    1. Drug: Cannabis, Medical
    MeSH:Infection Communicable Diseases Hepatitis C Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkin Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Wounds and Injuries Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic
    HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

    Primary Outcomes

    Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).

    Measure: Prevention of COVID-19

    Time: Five years

    Description: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).

    Measure: Treatment of COVID-19

    Time: Five years

    Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.

    Measure: Treatment of Symptoms

    Time: Five years

    Secondary Outcomes

    Description: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.

    Measure: Cannabis Impact on Quality of Life

    Time: Five years

    Description: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.

    Measure: Cannabis Route and Dosing

    Time: Five years

    Description: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.

    Measure: Monitoring Adverse Events

    Time: Five years
    2 A Novel and Practical Accelerated Low-frequency Right-sided Stimulation Protocol as a Substitute for Patients With Bipolar Depression Needing Electroconvulsive Therapy During the COVID-19 Pandemic

    The current study aims to assess the feasibility, acceptance and clinical outcomes of a practical high-dose LFR protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with bipolar depression previously responsive to ECT and patients needing urgent treatment due to symptom severity during the COVID-19 pandemic.

    NCT04427137
    Conditions
    1. Bipolar Depression
    Interventions
    1. Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil
    MeSH:Depression Depressive Disorder Bipolar Disorder
    HPO:Bipolar affective disorder Depressivity Mania

    Primary Outcomes

    Description: Less than or equal to 10 This scale is used to quantify the severity of symptoms of depression Scale range: 0-76 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Secondary Outcomes

    Description: changes in scores This scale is used to quantify the severity of symptoms of depression Scale range: 0-76 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Change in Hamilton Rating Scale for Depresion 24-it (HRSD-24)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in score This scale is used to quantify the severity of symptoms of depression Scale range: 0-76 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Response on Hamilton Rating Scale for Depresion 24-it (HRSD-24)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores This scale is used to quantify the severity of symptoms of mania Scale range: 0-60 (total score) Lower scores indicate lower severity of manic symptoms (i.e., better outcome) Higher scores indicate higher severity of manic symptoms (i.e., worse outcome)

    Measure: Change in Young Mania Rating Scale (YMRS)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Less than or equal to 4 This scale is used to quantify the severity of symptoms of depression Scale range: 0-27 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Remission on Patient Health Questionnaire (PHQ-9)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in score This scale is used to quantify the severity of symptoms of depression Scale range: 0-27 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Response on Patient Health Questionnaire (PHQ-9)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores This scale is used to quantify the severity of symptoms of depression Scale range: 0-27 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Change in Patient Health Questionnaire (PHQ-9)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Less than or equal to 4 This scale is used to quantify the severity of symptoms of anxiety Scale range: 0-21 (total score) Lower scores indicate lower severity of anxiety symptoms (i.e., better outcome) Higher scores indicate higher severity of anxiety symptoms (i.e., worse outcome)

    Measure: Remission on General Anxiety Disorder 7 item (GAD-7)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in score This scale is used to quantify the severity of symptoms of anxiety Scale range: 0-21 (total score) Lower scores indicate lower severity of anxiety symptoms (i.e., better outcome) Higher scores indicate higher severity of anxiety symptoms (i.e., worse outcome)

    Measure: Response on General Anxiety Disorder 7 item (GAD-7)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores This scale is used to quantify the severity of symptoms of anxiety Scale range: 0-21 (total score) Lower scores indicate lower severity of anxiety symptoms (i.e., better outcome) Higher scores indicate higher severity of anxiety symptoms (i.e., worse outcome)

    Measure: Change in General Anxiety Disorder 7 item (GAD-7)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Less than or equal to 12 This scale is used to quantify the severity of symptoms of depression Scale range: 0-63 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Remission on Beck Depression Inventory (BDI-II)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: 50% Reduction in Score This scale is used to quantify the severity of symptoms of depression Scale range: 0-63 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Response on Beck Depression Inventory (BDI-II)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores This scale is used to quantify the severity of symptoms of depression Scale range: 0-63 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)

    Measure: Change on Beck Depression Inventory (BDI-II)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Score of 0 This scale is used to assess the presence or absence of suicidal ideation and the degree of severity of suicidal ideas Scale range: 0 - 38 (total score) Lower scores indicate lower severity of suicidal ideation (i.e., better outcome) Higher scores indicate higher severity of suicidal ideation (i.e., worse outcome)

    Measure: Remission on Beck Scale for Suicidal Ideation (SSI)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores This scale is used to assess the presence or absence of suicidal ideation and the degree of severity of suicidal ideas Scale range: 0 - 38 (total score) Lower scores indicate lower severity of suicidal ideation (i.e., better outcome) Higher scores indicate higher severity of suicidal ideation (i.e., worse outcome)

    Measure: Change on Beck Scale for Suicidal Ideation (SSI)

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: changes in scores

    Measure: Change in WHO Disability Assessment Schedule (WHODAS) Range 0-38

    Time: Up to 10 days (From screening/baseline to end of the acute treatment)

    Description: Includes number of treatment days needed and number going on to receive ECT

    Measure: Proportion of Patients Maintaining Response During Relapse Prevention

    Time: 24 weeks (Tapering and Relapse prevention phase)

    HPO Nodes


    Reports

    Data processed on January 01, 2021.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook